NEWS AND PRESS
PRESS RELEASE: Reapplix receives US FDA 510(k) clearance
Reapplix today announced that it has received US FDA 510(k) clearance for its 3C Patch System™. Reapplix’s proprietary simple-to-use device technology has been cleared for the following indications for use:
New paper published studying the impact of LeucoPatch in chronic wounds
As each LeucoPatch contains a substantial number of leucocytes, the aim of the study was to investigate the activity of the polymorphonuclear neutrophils (PMNs) within the LeucoPatch.
Key patents granted in Europe and Eurasia
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in Europe and in Eurasia.
Patent news – Patent granted in Japan
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that a key patent has been granted in the Japan.
Patent news – Patents granted in China and Canada
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification of key patent grants in China and Canada.
Study Shows Effectiveness of LeucoPatch in Healing Diabetic Foot Ulcers
A newly published study using LeucoPatch, a unique active wound therapy, developed by Reapplix ApS (Reapplix), has been published showing that LeucoPatch was highly effective in healing diabetic foot ulcers.
Reapplix Patents Granted in USA and Japan
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in the United States and in Japan.
REAPPLIX ANNOUNCED AS INNOVATION PRIZE WINNER 2014 IN ‘THE ENGINEER’
Reapplix was today announced as the winner of ‘The Engineer’ Product Prize 2014 in the Innovation category.
REAPPLIX – 2014 EY ENTREPRENEUR OF THE YEAR FINALIST
Reapplix was chosen from the selected participants in the 2014 EY Entrepreneur Of The Year in Denmark as a top 3 finalist in the Life Sciences category.
PRESS RELEASE: CMS approves Reapplix clinical study for reimbursement coverage
Reapplix ApS (Reapplix), developers of the unique LeucoPatch® active wound therapy, have today announced that the Centers for Medicare and Medicaid Services (CMS) in the USA have approved Reapplix’s clinical research study protocol for Coverage with Evidence Development.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.